Is RxSight, Inc. (RXST) Overvalued?
We dive into why RxSight, Inc. (RXST) could be considered overvalued on 2026-08-18, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Commentary & Analysis
Why RxSight, Inc.’s (RXST) Stock Is Down 5.22%
As of Monday, August 17, RxSight, Inc.’s RXST share price has dipped by 5.22%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why RxSight, Inc.’s (RXST) Stock Is Up 6.77%
As of Tuesday, August 11, RxSight, Inc.’s RXST share price has surged by 6.77%, which has investors questioning if this is right time to sell.Jenna Brashear
Why RxSight, Inc.’s (RXST) Stock Is Down 10.41%
As of Thursday, August 06, RxSight, Inc.’s RXST share price has dipped by 10.41%, which has investors questioning if this is right time to buy.Michael Rose
What You Need to Know About RxSight, Inc.'s Q3 Earnings
RxSight, Inc.'s fiscal Q3 earnings report was released on Wednesday, August 05. Let's dive in to see if (RXST) missed or beat analyst's expectations.Michael Rose
Financial Summary
| Share Statistics | RXST | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $253.3 | $407.7 | 29% |
|
| Shares Out (Mil) | 41.5 | 41.3 | 43% |
|
| Institutional Ownership | 94.3% | 81.4% | 65% |
|
| Float (Mil) | 36.3 | 34.9 | 40% |
|
| Beta | 1.13 | 0.88 | 68% |
|
| Avg Daily Volume (000s) | 808 | 412 | 66% |
|
| Price Change (52-week) |
(30.9%) | 64.8% | 23% |
|
| Growth | RXST | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 55.7% | 11.8% | 96% |
|
| Net Income (5yr) | (27.8%) | (6.0%) | 15% |
|
| EPS (5yr) | (52.1%) | 10.4% | 3 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (44.5%) | (16.2%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.153) | ($0.275) | ($0.697) | |
| Month Ago EPS | ($0.168) | ($0.700) | ($0.560) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.168) | ($0.700) | ($0.560) | |
| Year/Year Chg | (47.6%) | (71.1%) | (76.4%) | |
| Financials | RXST | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $128 | $119 | 28% |
|
| Net Income (TTM) (Mil) | ($47) | ($9) | 17% |
|
| EPS (TTM) | ($1.139) | ($0.400) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($23) | ($3) | 14% |
|
| Net Cash Flow (TTM) (Mil) | ($27) | $1 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $9 | $21 | 27% |
|
| Enterprise Value (Q1) (Mil) | $55 | $427 | 17% |
|
| Valuation | RXST | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.96 | 3.06 | 20% |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | RXST | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.5% | 58.9% | 87% |
|
| Net Margin | (36.8%) | (6.9%) | 14% |
|
| ROA | (14.2%) | (12.7%) | 23% |
|
| ROE | (17.3%) | (13.1%) | 24% |
|
| Liabilities to Assets | 25.3% | 46.0% | 17% |
|
| F-Score | 3 | 4 | 18% |
|
RxSight, Inc. did not pass any screens on 8/20/2026.
